Novel considerations in the pathogenesis of the antiphospholipid syndrome: Involvement of the tissue factor pathway of blood coagulation

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 3, 2008, Pages 251-255

  Adams, Murray ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIBODY DETECTION; ANTICOAGULATION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING; CLINICAL FEATURE; ENDOTHELIUM CELL; FETUS WASTAGE; HUMAN; HYPERCOAGULABILITY; IMMUNOPATHOGENESIS; LABORATORY TEST; MONOCYTE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS; LUPUS COAGULATION INHIBITOR; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBIN; THROMBOPHILIA; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 50249172815     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1082268     Document Type: Review

References (35)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
2. Malia RG, Kitchen S, Greaves M, et al. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-107
3. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-2625
4. Amengual O, Atsumi T, Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281
5. Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-1332
6. Escolar G, Font J, Reverter JC, et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb 1992;12:196-200
7. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-250
8. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965
9. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007;27:1687-1693
10. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-843
11. Ederhy S, Di Angelantonio E, Mallat Z, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol 2007;100:989-994
12. Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle- associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527
13. Rauch U, Antoniak S. Tissue factor-positive microparticles in blood associated with coagulopathy in cancer. Thromb Haemost 2007;97:9-10
14. Werling RW, Zacharski LR, Kisiel W, et al. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993;69:366-369
15. Adams MJ, Oostryck R. A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples. Blood Coagul Fibrinolysis 2000;11:327-333
16. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S65-S72
17. Jeske W, Hoppensteadt D, Fareed J, et al. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S73-S80
18. Rustin MHA, Bull HA, Machin SJ, et al. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus in endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988;90:744-748
19. Hasselaar P, Derksen RH, Oosting JD, et al. Synergistic effect of low doses of tumour necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 1989;62:654-660
20. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986;137:1532-1537
21. Ferro D, Saliola M, Meroni PL, et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J Thromb Haemost 2003;1:523-531
22. Reverter JC, Tassies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998;41:1420-1427
23. Jacobsen EM, Sandset PM, Wisloff F. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Thromb Res 1999;94:213-220
24. Morel O, Jesel L, Freyssinet JM, et al. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J 2005;3:15
25. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004;91:667-673
26. Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007;33:771-779
27. Adams M, Breckler L, Stevens P, et al. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Haematologica 2004;89:985-990
28. Adams MJ, Donohoe S, Mackie IJ, et al. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001;114:375-379
29. Adams MJ, Dunstan RA, Oostryck R. Interference by lupus anticoagulant in a functional assay for tissue factor pathway inhibitor. Thromb Res 1995;80:435-440
30. Adams MJ, Oostryck R. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor. Thromb Res 1997;87:245-249
31. Lean SY, Ellery P, Ivey L, et al. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. Haematologica 2006;91:1360-1366
32. Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003;1:718-724
33. Salemink I, Blezer R, Willems GM, et al. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000;84:653-656
34. Liestol S, Sandset PM, Jacobsen EM, et al. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Br J Haematol 2007;136:131-137
35. Sheng Y, Hanly JG, Reddel SW, et al. Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. Clin Exp Immunol 2001;124:502-508